Lexapro Tapering Guide
escitalopram
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
Overview
Escitalopram is the therapeutically active S-enantiomer of citalopram, an SSRI used for the treatment of major depressive disorder and generalized anxiety disorder. It is considered one of the most selective SSRIs available.
5mg, 10mg, 20mg
Tablets: 5mg, 10mg, 20mg; Oral solution: 1mg/mL
Category C (risk cannot be ruled out)
Mechanism of Action
Selective serotonin reuptake inhibitor (SSRI) that binds with high affinity to the serotonin transporter (SERT), blocking reuptake of serotonin into the presynaptic neuron and increasing serotonergic neurotransmission.
Taper Notes
Hyperbolic taper recommended. Liquid formulation (1mg/mL) available for precise final cuts below 5mg.
Hyperbolic Tapering Guidance
Reduce by proportionally smaller amounts at lower doses. Final reductions (2.5mg → 0) are often the hardest. Consider liquid formulation for cuts below 2.5mg.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reductions | ~4 weeks | Larger dose steps are generally better tolerated early on. Your prescriber will determine appropriate increments. |
| Middle reductions | 4-6 weeks | Smaller dose changes become important. Liquid formulation may help with precision at lower doses. |
| Final reductions | 8-12 weeks | The lowest doses often require the slowest, most gradual approach. Discuss liquid formulation with your prescriber. |
Withdrawal Timeline
1-3 days after dose reduction
4-7 days
2-4 weeks for most symptoms
Brain zaps and emotional blunting may persist 1-3 months in some cases
Community Tips
Practical insights shared by members tapering Lexapro. Not medical advice — always consult your prescriber.
- 1Ask your prescriber about Lexapro liquid formulation — it allows more precise dose adjustments at lower doses.
- 2Brain zaps are the most commonly reported symptom. They tend to worsen toward the end of the taper.
- 3If you experience a wave of symptoms, talk to your prescriber about holding at your current dose before any further changes.
- 4Many members find the final stretch of tapering harder than earlier steps. Go slow and stay in touch with your prescriber.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (risk of serotonin syndrome)
- CYP2C19 inhibitors (e.g., omeprazole) may increase escitalopram levels
- Serotonergic drugs (triptans, tramadol, St. John's Wort) increase serotonin syndrome risk
Food Interactions
- Grapefruit juice may increase levels via CYP3A4 inhibition
- No significant food effect on absorption
Contraindications
- MAOIs within 14 days
- Pimozide
- Known hypersensitivity to escitalopram or citalopram
Toxicity
Serotonin syndrome at high doses or in combination with serotonergic agents. QT prolongation rare but dose-dependent.
Pharmacokinetics
ADME Profile
Rapidly absorbed after oral administration, Tmax ~5 hours, bioavailability ~80%, unaffected by food.
~12 L/kg
Hepatic via CYP3A4 and CYP2C19 to S-demethylcitalopram (S-DCT) and S-didemethylcitalopram (S-DDCT), both with minimal pharmacological activity.
Renal (~8% excreted unchanged) and hepatic metabolism.
~56%
~600 mL/min (oral clearance)
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Lexapro (escitalopram) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
- Framer A 2021 — The patient voice: an exploration of the experience of withdrawal from antidepressants (Therapeutic Advances in Psychopharmacology)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms from the Bruyère Research Institute
- Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on safely discontinuing antidepressants
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
- Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.